CD1-MR1 2025
Chairs: Paolo Dellabona & Andrew Chancellor
Sponsored by:
Arovella Therapeutics
Anti-tumor adjuvancy by human CD4+ iNKT cells (#57)
9:40 AM
Developing CAR-NKT cells to reprogram the Tumor Microenvironment in Prostate Cancer (#58)
10:05 AM